Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced the unexpected passing of its chairman and founder, Dr. Tachi Yamada, on August 4, 2021, at his home in Seattle, Washington.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced the unexpected passing of its chairman and founder, Dr. Tachi Yamada, on August 4, 2021, at his home in Seattle, Washington. The company expressed deep condolences to Dr. Yamada's family, highlighting his significant contributions to both Phathom and the field of gastroenterology. Dr. Yamada was recognized as a transformative figure in his industry. Phathom, specializing in treatments for gastrointestinal diseases, is advancing its late-stage development of vonoprazan, a novel treatment for acid-related disorders.
Positive
- Phathom's ongoing late-stage development of vonoprazan, a treatment for acid-related disorders, continues to progress.
Negative
- The sudden loss of Dr. Tachi Yamada may impact leadership continuity and strategic vision.
Details
News Market Reaction – PHAT
The recorded move for PHAT in the trading session of this news was +2.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the sad news that its chairman and founder, Dr. Tachi Yamada, passed away suddenly at his Seattle, Washington home on August 4.
“The entire Phathom community is devastated to learn of Tachi’s sudden passing and send our heartfelt condolences and prayers to the entire Yamada family,” said Terrie Curran, Phathom’s President and Chief Executive Officer. “Dr. Yamada was an extraordinary person and a tremendous leader, mentor, and friend. Beyond his many contributions to Phathom as our founder and chairman, Tachi was a legend in the gastroenterology community whose work was integral to some of the most important advancements in the field. His passing will leave an immeasurable void in the hearts of all who knew him.”
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at www.phathompharma.com or follow the Company on social media: LinkedIn at www.linkedin.com/company/phathompharma and Twitter @PhathomPharma.
CONTACTS
Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com
Investor Contact:
Joe Hand
1-877-742-8466
ir@phathompharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.